Posted on May 24th, 2012 by
During the upcoming annual meeting of the American Society of Clinical Oncology (ASCO), results will be presented from clinical trials involving potential new drugs under development for the treatment of multiple myeloma. In particular, results for newer, lesser known agents that are in the early stages of clinical development will take center stage. These agents include obatoclax, siltuximab, daratumumab, and SNS01-T…At ASCO, Dr. A. K. Stewart from the Mayo Clinic in Arizona will discuss results of a Phase 1 study of obatoclax in combination with Velcade (bortezomib) for the treatment of relapsed multiple myeloma.
Myeloma Beacon by Maike Haehle
You must be logged-in to the site to post a comment.